NCT03462719 2026-04-13
GLOW
Janssen Research & Development, LLC
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT03737981 2026-04-13
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04285567 2026-03-03
CRISTALLO
Hoffmann-La Roche
Phase 3 Completed
NCT03332017 2026-02-18
ROSEWOOD
BeOne Medicines
Phase 2 Completed
NCT03580928 2026-02-13
AVO
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02427451 2026-01-27
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1/2 Active not recruiting